Summary
FGEN Chart
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript
FibroGen, Inc. ( FGEN ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Thane Wettig - CEO & Director David DeLucia - Senior VP & CFO Conference Call Participants Gaia Vasiliver-Shamis Andy Hsieh Matthew Keller - H.C. Wainwright & Co, LLC, Research Division Chen Lin Presentation Operator Hello, and thank you for standing by.
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
FibroGen (FGEN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimate of a loss of $4.01. This compares to a loss of $4.25 per share a year ago.
FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript
FibroGen, Inc. (NASDAQ:FGEN ) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET Company Participants Carol Gaddum - Corporate Participant Product Team Lead - Corporate Participant David DeLucia - Chief Financial Officer Thane Wettig - CEO & Director Conference Call Participants Matthew Keller - H.C. Wainwright & Co, LLC, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C.
FibroGen, Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $5 | $5 | - | - |
 Anthony Scaramucci SkyBridge Capital II LLC | 400,000 | $2.49M | $3.51M | $1.02M | 41.13% |
FibroGen, Inc (FGEN) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
FibroGen, Inc Profile
| Biotechnology Industry | Healthcare Sector | Thane Wettig CEO | NASDAQ (NGS) Exchange | 31572Q881 CUSIP |
| US Country | 225 Employees | - Last Dividend | 17 Jun 2025 Last Split | 14 Nov 2014 IPO Date |
Overview
FibroGen, Inc. is a pioneering biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to address significant unmet medical needs. Since its establishment in 1993, the company has dedicated its efforts to advancing science and medicine in areas where they can make a substantial difference. With a head office located in San Francisco, California, FibroGen is at the forefront of biotechnological innovation, guided by collaboration agreements with global leaders like Astellas Pharma Inc. and AstraZeneca AB. This strategic positioning allows FibroGen to not only develop but also potentially deliver game-changing treatments on a worldwide scale.
Products and Services
- Pamrevlumab
A forefront innovation by FibroGen, Pamrevlumab, is a human monoclonal antibody that targets the connective tissue growth factor (CTGF). It is currently in Phase III clinical development for patients with locally advanced pancreatic cancer. By focusing on CTGF, Pamrevlumab aims to offer a novel treatment pathway for this challenging disease, potentially improving the survival and quality of life for patients facing pancreatic cancer.
- Roxadustat
This oral small molecule inhibitor marks a significant breakthrough in the treatment of anemia associated with chronic kidney disease (CKD) and myelodysplastic syndromes (MDS). By inhibiting hypoxia-inducible factor prolyl hydroxylase activity, Roxadustat addresses anemia by mimicking the body’s response to high altitudes, thus promoting red blood cell production. Successfully completing Phase III clinical development in various regions including China, Europe, and Japan, Roxadustat stands out as a critical advancement in managing CKD and MDS-related anemia.
